Glial fibrillary acidic protein (GFAP) refers to the type III intermediate filament proteins and is an essential component of the cytoskeleton in astrocytes of all vertebrates. This review presents current data on the molecular organization of GFAP in a comparative aspect. The results of most relevant studies using immunocytochemical labeling of the protein are summarized. The data on the changes in expression of GFAP in Alexander disease caused by the primary pathology of astrocytes are presented.
1 September 2015 in Journal of Evolutionary Biochemistry and Physiology
Assessment of the integrity, viability and functional state of nerve cells is a major problem in studying the effect of experimental exposures on different brain structures in vertebrates and...
1 September 2014 in Journal of Evolutionary Biochemistry and Physiology
The brain neurons synthesizing catecholamines are ones of the most studied populations of nerve cells. The most essential morphological difference of these cells in many mammalian species—the presence of pigment neuromelanin in their cytoplasm. The issue of role of neuromelanin in cell seems important for comparative neurobiology, as it not only is absent in neurons of different transmitter nature, but even in catecholaminergic neurons in some species of laboratory animals, which restricts possibilities of experimental testing of available hypotheses about its functions in norm and in pathology. For the last few years neuromelanin attracts particular interest in the researchers studying neurotoxicity and modulation of Parkinson’s disease. In the presented review there are generalized and analyzed novel data about structure and functions of neuromelanin, as well as discussed is its possible role in pathogenesis of Parkinson’s disease.
1 May 2013 in Journal of Evolutionary Biochemistry and Physiology
Using Perls’ histochemical method, iron was revealed in the brain structures of human and rat. Iron accumulation was observed in perivascular areas and neuropil of substantia nigra as well as in...
Hyperbaric oxygen (HBO2) inhibits the GABAergic function in the brain, leading to the development of convulsive reactions in the form of paroxysmal discharges on the EEG, as well as movement disorders, in a manner similar to a generalized epileptic seizure. We hypothesize that HBO2-induced deficiency of GABAergic neurotransmission due to suppression of GABA synthesis, can be overcome by blocking GABA clearance from the synaptic cleft and slowing down its enzymatic degradation. The present study aimed to explore the development of seizures in rats at 5 ATA of oxygen pressure after tiagabine-mediated blockade of GABA transporters and vigabatrin-mediated inhibition of GABA-transaminase. The data obtained in this study are as follows: (1) both vigabatrin-mediated inhibition of GABA transaminase and tiagabine-mediated inhibition of GABA transporters prevented the development of seizures in rats at 5 ATA of oxygen pressure; (2) HBO2-induced oxygen seizures arose with a decrease in the brain GABA concentration by 30–40% vs. the basal level; (3) vigabatrin-mediated inhibition of GABA transaminase prevented a decrease in the rat striatum GABA level at 5 ATA of oxygen pressure. Thus, a slowdown in synaptic GABA clearance or attenuation of enzymatic GABA degradation can compensate an HBO2-induced reduction in GABA synthesis, as well as raise the GABA concentration to a level sufficient for the restoration of GABAergic function, preventing thereby the development of convulsive syndrome.